Quest for the right Drug

|
עמוד הבית / אורסופאלק 500 / מידע מעלון לרופא

אורסופאלק 500 URSOFALK 500 (URSODEOXYCHOLIC ACID)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות מצופות פילם : FILM COATED TABLETS

Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1   Pharmacodynamic properties
Pharmacotherapeutic group/ATC code
ATC code: A05AA02 and A05B
Small amounts of ursodeoxycholic acid are found in human bile.

After oral administration, it reduces cholesterol saturation of the bile by inhibiting cholesterol absorption in the intestine and decreasing cholesterol secretion into the bile. Presumably as a result of dispersion of the cholesterol and formation of liquid crystals, a gradual dissolution of cholesterol gallstones occurs.

According to current knowledge, the effect of ursodeoxycholic acid in hepatic and cholestatic diseases is thought to be due to a relative exchange of lipophilic, detergent-like, toxic bile acids for the hydrophilic, cytoprotective, non-toxic ursodeoxycholic acid, to an improvement in the secretory capacity of the hepatocytes, and to immune-regulatory processes.

Pharmacokinetic Properties

5.2    Pharmacokinetic properties

Orally administered ursodeoxycholic acid is rapidly absorbed in the jejunum and upper ileum through passive transport and in the terminal ileum through active transport. The rate of absorption is generally 60-80%. After absorption, the bile acid undergoes almost complete hepatic conjugation with the amino acids glycine and taurine and is then excreted with the bile. First-pass clearance through the liver is up to 60%.
Depending on the daily dose and underlying disorder or condition of the liver, the more hydrophilic ursodeoxycholic acid accumulates in the bile. At the same time, a relative decrease in other more lipophilic bile acids is observed.

Under the influence of intestinal bacteria, there is partial degradation to 7-keto-lithocholic acid and lithocholic acid. Lithocholic acid is hepatotoxic and causes liver parenchyma damage in a number of animal species. In humans, only very small amounts are absorbed, which are sulphated in the liver and thus detoxified, before being excreted in the bile and ultimately in the faeces.

The biological half-life of ursodeoxycholic acid is 3.5-5.8 days.

שימוש לפי פנקס קופ''ח כללית 1994 Dissolution or reduction of size of radiolucent cholesterol gallstones in patients with a functioning gallbladder
תאריך הכללה מקורי בסל 01/01/1995
הגבלות תרופה שאושרה לשימוש כללי בקופ'ח

בעל רישום

RAFA LABORATORIES LTD

רישום

150 68 33832 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

25.02.16 - עלון לרופא

עלון מידע לצרכן

10.03.16 - עלון לצרכן אנגלית 10.03.16 - עלון לצרכן עברית 10.03.16 - עלון לצרכן ערבית 09.02.16 - החמרה לעלון

לתרופה במאגר משרד הבריאות

אורסופאלק 500

קישורים נוספים

RxList WebMD Drugs.com